Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HBM HoldingsFRA:6XY 64 FCF Margin % is 14.69% as of Dec. 2025. GuruFocus rates FRA:6XY with a GF Score™ of 64/100 and a GF Value™ of €0.74 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 952 Biotechnology companies, HBM Holdings ranks better than 96.22% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. HBM Holdings's Free Cash Flow for the
six
months ended in Dec. 2025 was €7.1 Mil. HBM Holdings's Revenue for the
six
months ended in Dec. 2025 was €48.4 Mil. Therefore, HBM Holdings's FCF Margin % for the quarter that ended in Dec. 2025 was 14.69%.
The historical rank and industry rank for HBM Holdings's FCF Margin % or its related term are showing as below:
FRA:6XY'
s FCF Margin % Range Over the Past 10 Years
Min: -3245.39 Med: -273.17 Max: 79.9
Current: 44.2
During the past 8 years, the highest FCF Margin % of HBM Holdings was 79.90%. The lowest was -3245.39%. And the median was -273.17%.
FRA:6XY's FCF Margin % is ranked better than 96.22% of 952
companies
in the Biotechnology industry
Industry Median: -82.715
vs FRA:6XY: 44.20
HBM Holdings FCF Margin % Related Terms
HBM Holdings FCF Margin % Historical Data
* Premium members only.
The historical data trend for HBM Holdings's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6XY vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, HBM Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's FCF Margin % distribution charts can be found below:
* The bar in red indicates where HBM Holdings's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (FRA:6XY) has a FCF Margin % of 14.69% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on HBM Holdings and its competitors. According to the industry distribution chart, HBM Holdings ranks #36 out of 952 companies in the Biotechnology industry, placing it in the top 3.8%.
Is HBM Holdings' FCF Margin % too high?
HBM Holdings' current FCF Margin % is 14.69%. Based on the distribution chart, HBM Holdings ranks #36 out of 952 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HBM Holdings has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #36 out of 952 companies for FCF Margin %. This places HBM Holdings in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on HBM Holdings and its competitors. HBM Holdings's current FCF Margin % is 14.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (FRA:6XY) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.74, compared to a current price of €1.33 — trading 79.7% above its estimated fair value. The current FCF Margin % is 14.69%. HBM Holdings' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For HBM Holdings (FRA:6XY), the current FCF Margin % is 14.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (FRA:6XY) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of €1.33 is trading 79.7% above its estimated GF Value™ of €0.74.
GuruFocus considers HBM Holdings to be Significantly Overvalued.
Key valuation signals for FRA:6XY:
FCF Margin %: 14.69%
GF Value™: €0.74 vs. price of €1.33 (79.7% above fair value)
No single metric tells the full story. See the FRA:6XY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
64GF Score
Get the complete analysis for FRA:6XY
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6XY has been successfully added to your 
